Biocon Biologics Eyes $1bn In Sales As Q2 Revenues Jump 40%
Strong growth in Biocon's biologics segment continued in the second quarter and the vertical has now set a target of $1bn in annual sales by the 2021-22 fiscal year.
You may also be interested in...
Biocon-Mylan’s sBLA approval for pegfilgrastim made at a new Indian site gets FDA go-ahead, facilitating a "multi-fold" scale up in capacity. But it will be interesting to watch how impactful this could be on market dynamics in the US, where more competition has arrived.
India’s Biocon has promised to cut by 50% the cost of recombinant human insulin to 10 cents a day in low- and middle-income nations to help make the life-saving medication “universally accessible.”
Biocon Biologics has acquired a biologics research facility in southern India from Pfizer that will employ 250 scientists and enable the company to pursue “breakthrough innovation.”